Hidden Costs and Fiduciary Risk in Employer Health Plans

For decades, the Employee Retirement Income Security Act (ERISA) has been one of the primary legal frameworks governing employer-sponsored benefits in the United States. Originally enacted in 1974 to protect retirement assets, ERISA has since become a powerful tool for plaintiffs challenging how companies manage employee benefit plans.

Historically, most ERISA litigation has focused on pension and retirement plans, particularly 401(k) plans. These cases have generated billions of dollars in settlements, driven by allegations of excessive fees, imprudent investment options, and breaches of fiduciary duty. 

Now, a similar trend is emerging in a different—but significantly larger—category: employer-sponsored health plans.

Employer health plans cover over 150 million Americans, representing one of the largest pools of managed assets and expenditures in the U.S. economy. Unlike retirement plans, however, health plans have historically operated with less transparency and less litigation risk. That dynamic is changing.

We’re now seeing an increase in ERISA litigation targeting health plans, as new disclosure requirements, rising healthcare costs, and greater data availability expose potential fiduciary breaches. For plaintiff firms, this represents a new frontier of large-scale, data-driven litigation.

The Hidden Inefficiencies in Health Plans

At the core of ERISA is a simple principle: employers and plan fiduciaries must act solely in the interest of plan participants. In the context of health plans, this duty is increasingly being tested.

One of the biggest drivers of litigation is the lack of transparency and oversight in healthcare spending, particularly in areas like prescription drug pricing and third-party service provider fees.

Pharmacy Benefit Managers (PBMs), for example, play a central role in negotiating drug prices, but their pricing structures are often opaque. Plaintiffs are beginning to argue that employers have failed to adequately monitor these arrangements, resulting in inflated drug costs for employees and plan participants.

‍

Similarly, administrative costs and vendor relationships are coming under scrutiny. Employers frequently rely on consultants, brokers, and third-party administrators to manage health plans. Lawsuits increasingly allege that these intermediaries may receive hidden compensation or operate under conflicts of interest, raising questions about whether fiduciaries are fulfilling their obligations under ERISA.

Another emerging issue is the design and structure of health plans themselves. Plaintiffs are starting to challenge whether certain plan options are unnecessarily expensive or poorly structured, arguing that employers could have offered more cost-effective alternatives.

What ties these issues together is scale: even small inefficiencies, when applied across thousands of employees, can result in significant aggregate harm - making these cases highly attractive for class action litigation.

A Look Inside ERISA Health Plan Litigation

Recent lawsuits illustrate how ERISA health plan litigation is evolving and expanding.

One prominent example comes from lawsuits challenging how employers oversee prescription drug pricing within their health plans. In Seth Stern v. JPMorgan Chase & Co., plaintiffs allege that the company breached its ERISA fiduciary duties by allowing its PBM to charge excessive prices for prescription drugs, including widely used medications that were available at significantly lower costs elsewhere. The case reflects a broader trend: plaintiffs are increasingly scrutinizing whether employers are adequately monitoring PBMs and negotiating fair pricing, rather than passing avoidable costs onto plan participants.

In addition, a growing number of cases are targeting administrative and recordkeeping fees, drawing clear parallels to the earlier wave of 401(k) litigation. Plaintiffs argue that, like retirement plans, employer-sponsored health plans should be subject to rigorous benchmarking and cost controls - and that failing to monitor these expenses may constitute a breach of fiduciary duty. These claims reflect a broader shift toward applying established ERISA fee litigation theories to the health plan context, particularly as transparency around healthcare costs continues to increase.

The Shift Toward Data-Driven ERISA Litigation

Unlike many traditional areas of litigation, these cases rely on large, complex datasets: plan disclosures, healthcare claims, prescription pricing data, vendor contracts, and regulatory filings. Historically, this information has been fragmented and difficult to analyze - limiting the ability of plaintiff firms to identify potential claims at scale.

That is beginning to change.

Advances in legal intelligence and data analysis now make it possible to detect patterns across thousands of health plans, uncovering systemic issues that would otherwise remain hidden. By aggregating and analyzing data across comparable plans, it becomes easier to identify outliers in administrative costs, unusual pricing patterns in prescription drugs, or inconsistencies in how vendors are compensated. Connections between healthcare spending, contractual arrangements, and regulatory disclosures can start to reveal where fiduciary oversight may be falling short.

As these capabilities mature, legal intelligence platforms can help surface potential fiduciary breaches before they evolve into widely litigated cases.

This represents a significant shift for plaintiff firms - from reactive litigation based on individual complaints to proactive, data-driven case discovery.

‍